Literature DB >> 26985398

Spatial separation of the processing and MHC class I loading compartments for cross-presentation of the tumor-associated antigen HER2/neu by human dendritic cells.

Renato B Baleeiro1, René Rietscher2, Andrea Diedrich3, Justyna A Czaplewska4, Claus-Michael Lehr5, Regina Scherließ3, Andrea Hanefeld6, Michael Gottschaldt4, Peter Walden1.   

Abstract

Cross-presentation is the process by which professional antigen presenting cells (APCs) (B cells, dendritic cells (DCs) and macrophages) present endocytosed antigens (Ags) via MHC-I to CD8+ T cells. This process is crucial for induction of adaptive immune responses against tumors and infected cells. The pathways and cellular compartments involved in cross-presentation are unresolved and controversial. Among the cells with cross-presenting capacity, DCs are the most efficient, which was proposed to depend on prevention of endosomal acidification to block degradation of the epitopes. Contrary to this view, we show in this report that some cargoes induce strong endosomal acidification following uptake by human DCs, while others not. Moreover, processing of the tumor-associated antigen HER2/neu delivered in nanoparticles (NP) for cross-presentation of the epitope HER2/neu369-377 on HLA-A2 depended on endosomal acidification and cathepsin activity as well as proteasomes, and newly synthesized HLA class I. However, the HLA-A*0201/HER2/neu369-377 complexes were not found in the endoplasmic reticulum (ER) nor in endolysosomes but in hitherto not described vesicles. The data thus indicate spatial separation of antigen processing and loading of MHC-I for cross-presentation: antigen processing occurs in the uptake compartment and the cytosol whereas MHC-I loading with peptide takes place in a distinct subcellular compartment. The findings further elucidate the cellular pathways involved in the cross-presentation of a full-length, clinically relevant tumor-associated antigen by human DCs, and the impact of the vaccine formulation on antigen processing and CD8+ T cell induction.

Entities:  

Keywords:  HER2/neu; cancer; cross-presentation; dendritic cells; nanoparticles; tumor-associated antigens; vaccine

Year:  2015        PMID: 26985398      PMCID: PMC4792485          DOI: 10.1080/2162402X.2015.1047585

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  50 in total

1.  Mobilization of MHC class I molecules from late endosomes to the cell surface following activation of CD34-derived human Langerhans cells.

Authors:  P A MacAry; M Lindsay; M A Scott; J I Craig; J P Luzio; P J Lehner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

2.  ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells.

Authors:  Pierre Guermonprez; Loredana Saveanu; Monique Kleijmeer; Jean Davoust; Peter Van Endert; Sebastian Amigorena
Journal:  Nature       Date:  2003-09-25       Impact factor: 49.962

3.  Phagosomes are competent organelles for antigen cross-presentation.

Authors:  Mathieu Houde; Sylvie Bertholet; Etienne Gagnon; Sylvain Brunet; Guillaume Goyette; Annie Laplante; Michael F Princiotta; Pierre Thibault; David Sacks; Michel Desjardins
Journal:  Nature       Date:  2003-09-25       Impact factor: 49.962

4.  A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation.

Authors:  Eric Reits; Joost Neijssen; Carla Herberts; Willemien Benckhuijsen; Lennert Janssen; Jan Wouter Drijfhout; Jacques Neefjes
Journal:  Immunity       Date:  2004-04       Impact factor: 31.745

5.  Primary CD8+ T-cell response to soluble ovalbumin is improved by chloroquine treatment in vivo.

Authors:  Bruno Garulli; Maria G Stillitano; Vincenzo Barnaba; Maria R Castrucci
Journal:  Clin Vaccine Immunol       Date:  2008-08-27

6.  Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I.

Authors:  Tiziana Di Pucchio; Bithi Chatterjee; Anna Smed-Sörensen; Sandra Clayton; Adam Palazzo; Monica Montes; Yaming Xue; Ira Mellman; Jacques Banchereau; John E Connolly
Journal:  Nat Immunol       Date:  2008-03-30       Impact factor: 25.606

Review 7.  Cellular immunity to the Her-2/neu protooncogene.

Authors:  Rolf Kiessling; W Z Wei; F Herrmann; J A Lindencrona; A Choudhury; K Kono; B Seliger
Journal:  Adv Cancer Res       Date:  2002       Impact factor: 6.242

8.  Rab27a regulates phagosomal pH and NADPH oxidase recruitment to dendritic cell phagosomes.

Authors:  Carolina Jancic; Ariel Savina; Christina Wasmeier; Tanya Tolmachova; Jamel El-Benna; Pham My-Chan Dang; Steve Pascolo; Maire-Anne Gougerot-Pocidalo; Graça Raposo; Miguel C Seabra; Sebastian Amigorena
Journal:  Nat Cell Biol       Date:  2007-03-11       Impact factor: 28.824

9.  Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells.

Authors:  F Berard; P Blanco; J Davoust; E M Neidhart-Berard; M Nouri-Shirazi; N Taquet; D Rimoldi; J C Cerottini; J Banchereau; A K Palucka
Journal:  J Exp Med       Date:  2000-12-04       Impact factor: 14.307

10.  Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.

Authors:  P Paglia; C Chiodoni; M Rodolfo; M P Colombo
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

View more
  5 in total

Review 1.  Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

Authors:  Mariona Cabo; Rienk Offringa; Laurence Zitvogel; Guido Kroemer; Aura Muntasell; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-30       Impact factor: 8.110

Review 2.  Synthetic Biodegradable Microparticle and Nanoparticle Vaccines against the Respiratory Syncytial Virus.

Authors:  Patricia A Jorquera; Ralph A Tripp
Journal:  Vaccines (Basel)       Date:  2016-12-02

3.  Type I IFN and not TNF, is Essential for Cyclic Di-nucleotide-elicited CTL by a Cytosolic Cross-presentation Pathway.

Authors:  Darío Lirussi; Thomas Ebensen; Kai Schulze; Stephanie Trittel; Veronica Duran; Ines Liebich; Ulrich Kalinke; Carlos A Guzmán
Journal:  EBioMedicine       Date:  2017-07-19       Impact factor: 8.143

4.  Generation of populations of antigen-specific cytotoxic T cells using DCs transfected with DNA construct encoding HER2/neu tumor antigen epitopes.

Authors:  Maria Kuznetsova; Julia Lopatnikova; Julia Khantakova; Rinat Maksyutov; Amir Maksyutov; Sergey Sennikov
Journal:  BMC Immunol       Date:  2017-06-20       Impact factor: 3.615

5.  Human in vivo-generated monocyte-derived dendritic cells and macrophages cross-present antigens through a vacuolar pathway.

Authors:  Tsing-Lee Tang-Huau; Paul Gueguen; Christel Goudot; Mélanie Durand; Mylène Bohec; Sylvain Baulande; Benoit Pasquier; Sebastian Amigorena; Elodie Segura
Journal:  Nat Commun       Date:  2018-07-02       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.